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Abstract 
Introduction: Acinetobacter baumannii is an important human nosocomial pathogen; most clinical 
isolates are multidrug-resistant (MDR). Infections caused by A. baumannii often lead to high morbidity 
and mortality, with limited treatment options. Owing to the small number of anti-Gram-negative 
antibiotics in the development pipeline, researchers are looking to other natural compounds. The aim 
of this study was to determine the in vitro kill kinetics, in vivo efficacy and toxicity of theaflavin-
epicatechin combinations against MDR A. baumannii.  
Methods: Kill-kinetic assays were performed in Mueller Hinton 2 broth over 24 h. Toxicity of the 
compound in the insect model, Galleria mellonella was investigated. The effect of theaflavin-
epicatechin combinations on mortality and morbidity were assessed in Acinetobacter baumannii 
infected G. mellonella. Larvae were scored for morbidity (melanisation: scale; 0-4) and mortality over 
96 h.  
Results: Kill-kinetic assays revealed that monotherapy had bacteriostatic activity over 24 h, whereas 
theaflavin-epicatechin combinations were bactericidal (a >3 log reduction in bacterial numbers at 24 
h compared with the starting inoculum). Both polyphenols were non-toxic to G. mellonella at 
concentrations of up to 1000 mg/kg. In vivo treatment assays showed that the combination 
significantly increased (t-test; p = <0.05) larval survival at 96 h to 86% (±17 standard deviation 
percentage points [pp]) compared to monotherapy with theaflavin (52% ±14 pp), epicatechin (44% 
±25 pp) or PBS (31% ±13 pp). Morbidity was also lower in larvae treated with the combination, 
compared to monotherapy. 
Conclusions: Polyphenol combinations produce effective antibacterial action against A. baumannii 
and show great potential for the treatment of infections caused by MDR A. baumannii.  
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Introduction 
Acinetobacter baumannii is an important human nosocomial pathogen, often referred to an ESKAPE 
pathogen (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter species), harbouring multiple genes 
associated with antimicrobial resistance [1]. Hospital-acquired infections caused by A. baumannii, 
often lead to increased morbidity and mortality [2], due to limited antibiotic therapies. Antibiotics of 
last resort, such as tigecycline and colistin are increasingly used, but with the emergence of resistance 
to these drugs, clinicians may resort to unorthodox antibiotic combination therapies [3].  
 
Potential alternatives to antibiotics includes metal nanoparticles and plant derived compounds such 
as polyphenols. Polyphenols play an important role in plant defence systems against microbial 
pathogens [4]. Several studies have shown that polyphenols have antimicrobial activity against human 
and animal pathogens including bacteria, fungi and viruses [5-8]. 
 
Synergistic activity between polyphenols and some traditional antibiotics has been observed against 
multidrug-resistant bacteria [9-12]. Similarly, combinations of polyphenols have shown to be very 
effective at inhibiting bacterial growth in vitro, with higher concentrations also leading to cell death 
[13-15]. However, no data exists on the in vivo activity of polyphenol combinations. A model where 
the in vivo efficacy of polyphenol combinations can rapidly be determined, is the greater wax moth 
larvae, Galleria mellonella. This Lepidopteran is now a popular model for experimental bacteraemia 
studies, due to its high throughput, lack of Home Office restrictions and an innate immune system 
comparable with that of mammals [16]. Until recently, one disadvantage of the G. mellonella model 
was the lack of standardisation between suppliers, leading to high standard error and poor 
reproducibility across assays, making statistical analysis difficult. However, a standardised model, with 
controlled age, size and food supply is now available. Using the TruLarv G. mellonella model 
(Biosystems Technology, Exeter, UK), highly reproducible data can be produced. 
 
The aim of this study was to determine the in vitro kill kinetics and the in vivo toxicity and efficacy of 
theaflavin-epicatechin combinations against MDR strains of A. baumannii in the TruLarv G. mellonella 
model of infection. 
 
Methods 
Chemicals, media and bacterial isolates  
Epicatechin (≥ 90 %) powder, Luria broth base and Mueller-Hinton 2 agar/broth were purchased from 
SigmaAldrich (Dorset, UK). Theaflavin (≥ 95 %) was donated by Unilever (Bedford, UK). Type strain A. 
baumannii ATCC 19606 was purchased from Pro-Lab Diagnostics (Wirral, UK). Clinical isolates (n = 6) 
[17] were obtained from the Royal London Hospital (Whitechapel, UK) where they were identified via 
standard biochemical methods and Maldi-TOF. Isolates represent major clonal strains from the United 
Kingdom. All isolates were stored long term on cryobeads at -80°C. 
 
Antimicrobial susceptibility testing  
Minimum inhibitory concentrations (MICs) of theaflavin and epicatechin were determined alone and 
in combination against all 6 MDR isolates, performed in 96-well microtitre plates using Mueller Hinton 
2 cation-adjusted broth. Checkerboard assays were used with 2-fold decreasing concentrations of 
theaflavin (512-0 mg/L) and epicatechin (1024-0 mg/L) with a bacterial inoculum of 105 colony forming 
units (CFU) per mL. Plates were incubated at 37 °C for 24 h. Where the MIC was not determined, the 
dilution above the maximum dose was used in calculating the fractional inhibitory concentration 
indices (FICIs). Fractional inhibitory concentration indices were calculated using the following 
equation, as previously described [18]: FICI = FIC of A (MIC of antibiotic A in combination with 
antibiotic B/MIC of antibiotic A alone) + FIC of B (MIC of antibiotic B in combination with antibiotic 
A/MIC of antibiotic B alone). FICI values of ≤ 0.5 suggest a synergistic interaction, > 0.5−1.0 as an 
additive effect, > 1.0 to < 4 as indifference and a value of ≥ 4.0 was classed as an antagonistic effect 
[19]. All experiments were performed in triplicate, on three separate occasions. 
 
Kill-kinetic assays  
Kill-kinetic assays were performed using strains AB12, AB16, AB210 and the ATCC 19606 type strain. 
Isolates AB12, AB16 and AB210 were used as they represent the important clonal groups in the UK 
[17, 20]. In brief, a 1/1000 dilution of an 18 h bacterial culture, equating to approximately 106 CFU/mL 
was used as the starting inoculum for each strain. To individual cultures, antimicrobials were added at 
the following final concentrations: Theaflavin (0.5 mg/mL), epicatechin (0.5 mg/mL) and theaflavin 
and epicatechin combination (0.5 mg/mL + 0.5 mg/mL). Cultures were incubated at 37 °C under 
continuous agitation (225 rpm) for 24 h. At set time intervals of 0, 2, 4, 6 and 24 h post inoculation, 
100 μL samples were collected, serially diluted and plated onto Mueller Hinton 2 agar. Viable counts 
were performed after incubation at 37 °C for 20 h.  
 
In vivo toxicity in Galleria mellonella  
In vivo testing was conducted using the Galleria mellonella invertebrate model (TruLarvTM, Biosystems 
Technology, Exeter). In brief, ten larvae were injected via the left proleg with 10, 20, 40, 60, 80, 100, 
200, 400, 600, 800 and 1000 mg/kg doses of theaflavin or epicatechin freshly prepared in phosphate 
buffered saline (PBS). PBS was used in the control injections. Larve were incubated at 37°C for 96 h 
and were observed every 24 hours. The degree of melanisation and mortality was recorded at each 
observational time point. 
 
Inoculum testing 
To determine the optimum inoculum for staggered larval killing (Approx. 80 % mortality of larvae at 
96 h post infection), an inoculum test was performed. In brief, a 16 h culture of A. baumannii strains 
AB12, AB16, AB210 and the type strain ATCC 19606 in LB broth were washed in PBS before being 
serially dilute. Colony forming units were determined after plating the dilutions on nutrient agar and 
incubating at 37 °C for 24 h. Ten G. mellonella larvae were infected with the 16 h culture dilutions, 
equating to 103, 104, 105 and 106 CFU/larvae, via a 10 µL injection into the left proleg. Larvae were 
incubated at 37 °C and scored for survival (live/dead) at 0, 24, 48, 72 and 96 h.  
 
Treatment assays 
Sixteen larvae were infected with 105 CFU/larvae of ATCC 19606, AB12, AB16 or AB210. Thirty minutes 
post-inoculation, a second injection was administered of theaflavin (20 mg/kg in PBS), epicatechin (40 
mg/kg in PBS), a combination of theaflavin and epicatechin (20 + 40 mg/kg) or PBS. Larvae were 
incubated at 37 °C in petri dishes lined with WhatmanTM filter paper and scored for survival (live/dead) 
at 0, 24, 48, 72 and 96 h.  All insects were also scored for melanisation over 96 h. Melanisation was 
quantified based on a reversed scoring method [16], whereby a score of 4 indicated total melanisation 
of the larvae, 2 equalled melanin spots over the larvae, 1 equalled discolouration of the tail and a 
score of 0 equalled no melanisation. All in vivo experiments were carried out in triplicate on 3 separate 
occasions. 
 
Statistical analyses 
Time−kill curves (CFU/mL vs time) and survival curves were plotted using GraphPad Prism 7.0 
software. Synergy was defined as bactericidal activity (≥2 log10 difference in CFU/mL) of the 
combination compared to the single agent after 24 h incubation. Unpaired student t-tests were 
performed to check for significant variance.  
 
Survival curves were analysed using the log rank test with a p value of ≤0.05 indicating statistical 
significance. At the 96-h time-point, percentage survival of all antibiotic-treated larvae was calculated 
using combined data from replicate experiments. One-tailed, unpaired t tests were used to compare 
mean values, as described previously [21]. 
 
Results 
Broth microtitre testing revealed high MICs for both theaflavin and epicatechin (256-512 mg/L and 
1024-2048 mg/L, respectively) against all A. baumannii isolates tested (Table 1). However, when used 
in combination, MICs were significantly (p = <0.05) reduced for both theaflavin and epicatechin (16-
64 mg/L and 16-512 mg/L, respectively). The FICs indicate synergistic activity of the theaflavin and 
epicatechin combination (≤0.5).  
 
Data from the kill kinetic assays showed that A. baumannii exposed to epicatechin alone regrew (2-3 
log10 CFU/mL) after 24 h (Fig. 1). No significant difference between EC and the no drug control was 
observed. In 2/3 isolates tested, theaflavin produced bacteriostatic activity, with CFU/mL maintained 
over 24 h. However, with AB210, regrowth was observed after 4 h.  The combination of theaflavin and 
epicatechin had a greater impact than any agent alone on the kill kinetics of A. baumannii. For ATCC 
19606, a >2 log10 reduction in CFU/mL at 24 h was observed. However, significant (p ≤0.05) differences 
were observed between the combination and monotherapy alone against AB12, AB16 and AB210, 
with a >3 log10 reduction in CFU/mL at 24 h, indicating synergy and bactericidal activity.  
 
Results from the in vivo toxicity testing showed no insect deaths after injection with any of the 
polyphenols at any concentration over 96 h. No melanisation was observed in any insect, indicating 
the absence of observable, phenotypic toxicological effects of theaflavin and epicatechin in Galleria 
mellonella.  
 
Data from the in vivo treatment assays suggest that monotherapy with theaflavin or epicatechin 
affords greater larval survival than PBS over 96 h with overall survival rates of 52% (+/- 14 standard 
deviation percentage points [pp]) and 44 (+/- 22 pp), respectively (Fig. 2). However, when treated with 
the theaflavin-epicatechin combination, larval survival rates significantly increased to 86% (17 pp) (p 
= <0.05).  
 
High levels of morbidity were observed over 96 h in A. baumannii-infected larvae, ‘treated’ with PBS 
alone (Fig. 3). Medium to high melanisation scores were recorded at 96 h for infected larvae treated 
with theaflavin or epicatechin monotherapy. Low melanisation scores were observed for the 
theaflavin-epicatechin combination.  
 
Discussion 
The high MICs for theaflavin and epicatechin were not unexpected and are likely due to non-specific 
binding and/or degradation/dimerization of the polyphenols, which has been previously highlighted 
as factors reducing activity [22, 23]. 
 Data from the time-kill assays clearly demonstrated that the theaflavin-epicatechin combination was 
not only synergistic, but also bactericidal. This confirms previous kill-kinetic studies using 
polyphenolics, which also show combinations of polyphenols are synergistic and significantly reduce 
CFU/mL [24]. 
 
The lack of toxicity, at high administrated concentrations, may provide greater support for the use of 
polyphenols as treatments for bacterial infections. However, these observations might be due, in part, 
to the natural diet of G. mellonella larvae, which includes bee honeycomb that is naturally abundant 
in phenolic and polyphenolic compounds [25]. Therefore, G. mellonella larvae may have evolved to 
tolerate such compounds. Potential toxicity should be further assessed in mammalian models. 
 
Data from the in vivo treatment assays demonstrated that monotherapy with either theaflavin or 
epicatechin was more efficacious than ‘treatment’ with PBS alone. Previous studies using 
Caenorhabditis elegans [26] found monotherapy with epigallocatechin gallate (EGCG) increased 
survival rates of Escherichia coli infected nematodes by 28.9% to 76% compared with uninfected 
controls. However, the C. elegans model is incubated at 25°C and not 37°C as with G. mellonella and 
infection/treatment relies on the animal’s ability to consume the inoculum/antimicrobial. This might 
have had an impact on the growth of the bacteria and therefore the susceptibility to EGCG. Treatment 
with the polyphenol combination was significantly more effective at preventing larval death then 
monotherapy. These data support the use of combination therapies and clearly demonstrate that the 
theaflavin-epicatechin combination is an effective treatment in an invertebrate in vivo model of 
infection. 
 
High melanisation scores are indicative of a substantial immune response. The medium to high 
melanisation scores of larvae treated with theaflavin/epicatechin indicate that monotherapy is not 
adequate for reducing morbidity. A significantly reduced, phenotypically detected immune response 
was observed in larvae treated with the theaflavin-epicatechin combination. This indicates that the 
combination reduced overall morbidity and mortality, compared to monotherapy. Further studies 
using mammalian models are now warranted. 
 
The number of clinical isolates used, although representative of epidemic clonal groups in the UK, was 
relatively small and is thus a limitation of this work. Another limitation of note is the use of an 
invertebrate model of infection, which lacks an adaptive immune response and the detoxification 
systems found in mammals.   
 
Conclusions 
Polyphenol combinations show great potential for the treatment of infections caused by MDR A. 
baumannii. Significant increases in survival were observed when A. baumannii-infected larvae were 
treated with a theaflavin-epicatechin combination, compared with monotherapy. To our knowledge, 
this is the first study to unequivocally demonstrate antibacterial activity of polyphenols in G. 
mellonella and the first in vivo report where combinations of polyphenols have showed antibacterial 
activity against bacterial pathogens. 
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Table 1. Mean minimum inhibitory concentrations and fractional inhibitory concentrations for theaflavin (TF) and epicatechin (EC) alone and in combination 
versus multidrug-resistant Acinetobacter baumannii. 
 
Isolates 
Description MIC (mg/L) MIC in combination (mg/L) 
FICI 
 TF EC TF EC 
A. baumannii NCTC 19606 Type Strain 512 2048 64 32 0.14 
A. baumannii AB12 Clinical isolate of PFGE-defined UK lineage: ‘South East Clone’  512 2048 16 16 0.04 
A. baumannii AB16 Clinical isolate of PFGE-defined UK lineage: ‘Clone 2’ 256 1024 64 128 0.38 
A. baumannii AB184 Clinical isolate of PFGE-defined UK lineage: ‘T’ 256 1024 64 256 0.50 
A. baumannii AB186 Clinical isolate of PFGE-defined UK lineage: ‘Burn’ 512 2048 16 512 0.28 
A. baumannii AB210 Clinical isolate of PFGE-defined UK lineage: ‘Clone 1’ 512 2048 32 16 0.07 
A. baumannii AB211 Clinical isolate of PFGE-defined UK lineage: ‘Clone 1’ 256 1024 64 256 0.50 
 
 
 
  
 Fig. 1. Kill kinetics of epicatechin (EC), theaflavin (TF), EC + TF combinations and a Mueller-Hinton 
control versus multidrug-resistant Acinetobacter baumannii strains a) ATCC 19696, b) AB12, c) AB16 
and d) AB210. 
 
 
 
Fig. 2. Survival curves for Galleria mellonella infected with 104 CFU/larvae of multidrug-resistant A. 
baumannii strains a) ATCC 19696, b) AB12, c) AB16 and d) AB210, treated with phosphate buffered 
saline (PBS), epicatechin (EC), theaflavin (TF) or EC + TF combinations. 
 
 Fig. 3. Effect of treatments of phosphate buffered saline (PBS), epicatechin (EC), theaflavin (TF) or EC 
+ TF combination on morbidity (melanisation) over 96 h in Galleria mellonella infected with 104 
CFU/larva Acinetobacter baumannii a) ATCC 19696, b) AB12, c) AB16 and d) AB210, with higher 
melanisation scores indicating greater morbidity. 
 
